Skip to main content
. 2017 Aug 14;20(2):249–258. doi: 10.1093/neuonc/nox154

Fig. 1 .

Fig. 1

Best tumor size change from baseline in target lesion per IRF using modified RANO criteria in patients who had measurable disease at baseline and ≥1 evaluable postbaseline radiographic scan. Lines indicate the threshold for response and progression per RANO criteria, ≥50% decrease and ≥25% increase, respectively. Partial responses were confirmed in 6 patients in the 140 mg/day group and 17 in the 100 mg/day group. *Confirmed partial response.